{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:19:50Z","timestamp":1791404390571,"version":"4.3.3"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM140862"],"award-info":[{"award-number":["R35GM140862"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007710","name":"University of Connecticut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA241194"],"award-info":[{"award-number":["R01CA241194"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Toxicology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cotox.2022.100373","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T13:50:34Z","timestamp":1666360234000},"page":"100373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Nephrotoxicity of marketed antisense oligonucleotide drugs"],"prefix":"10.1016","volume":"32","author":[{"given":"Hangyu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"Wahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feryal","family":"Alhamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvi","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SooWan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Bahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-5415","authenticated-orcid":false,"given":"Xiao-bo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-9193","authenticated-orcid":false,"given":"Jos\u00e9 E.","family":"Manautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cotox.2022.100373_sref1","first-page":"2004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cotox.2022.100373_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/pharmaceutics14020260","article-title":"Oligonucleotide therapeutics: from discovery and development to patentability","volume":"14","author":"Moumne","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cotox.2022.100373_sref3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/dmd.121.000417","article-title":"Absorption, distribution, metabolism, and excretion of US Food and drug administration-approved antisense oligonucleotide drugs","volume":"50","author":"Migliorati","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cotox.2022.100373_bib4","article-title":"Alnylam announces FDA approval of AMVUTTRA\u2122 (vutrisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in Adults635","author":"Alnylam Pharamceuticals","year":"2022","journal-title":"Business Wire"},{"key":"10.1016\/j.cotox.2022.100373_sref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114196","article-title":"Antisense drug discovery and development technology considered in a pharmacological context","volume":"189","author":"Crooke","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cotox.2022.100373_sref6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse drug reactions and toxicity of the Food and drug administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cotox.2022.100373_bib7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.cotox.2022.100373_bib8","series-title":"SPINRAZA (nusinersen) injection for intrathecal use","year":"2016"},{"key":"10.1016\/j.cotox.2022.100373_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.omtn.2019.08.025","article-title":"Therapy with 2'-O-me phosphorothioate antisense oligonucleotides causes reversible proteinuria by inhibiting renal protein reabsorption","volume":"18","author":"Janssen","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cotox.2022.100373_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/nat.2019.0829","article-title":"Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia","volume":"30","author":"Narayanan","year":"2020","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.cotox.2022.100373_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cotox.2022.100373_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40259-021-00486-7","article-title":"Restoring protein expression in neuromuscular conditions: a review assessing the current state of exon skipping\/inclusion and gene therapies for Duchenne muscular dystrophy and spinal muscular atrophy","volume":"35","author":"Sheikh","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.cotox.2022.100373_bib13","doi-asserted-by":"crossref","first-page":"R1517","DOI":"10.1152\/ajpregu.2000.279.5.R1517","article-title":"Neural control of the kidney: functionally specific renal sympathetic nerve fibers","volume":"279","author":"DiBona","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.cotox.2022.100373_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semnephrol.2013.04.006","article-title":"Acid-base and potassium homeostasis","volume":"33","author":"Lee Hamm","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.cotox.2022.100373_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.14797\/mdcj-14-4-305","article-title":"The kidney as an endocrine organ","volume":"14","author":"Acharya","year":"2018","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.cotox.2022.100373_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","article-title":"Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity","volume":"26","author":"Volarevic","year":"2019","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.cotox.2022.100373_bib17","first-page":"550","article-title":"Drug-induced acute kidney injury: diverse mechanisms of tubular injury","volume":"25","author":"Perazella","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.cotox.2022.100373_sref18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109662","article-title":"Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules","volume":"349","author":"Guan","year":"2021","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.cotox.2022.100373_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.critrevonc.2019.03.004","article-title":"Role of epigenetic mechanisms in cisplatin-induced toxicity","volume":"137","author":"Quintanilha","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cotox.2022.100373_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semnephrol.2018.12.005","article-title":"Epigenetic regulation in kidney toxicity: insights from cisplatin nephrotoxicity","volume":"39","author":"Xiang","year":"2019","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.cotox.2022.100373_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14740338.2020.1747431","article-title":"An overview of statin-induced myopathy and perspectives for the future","volume":"19","author":"Nikolic","year":"2020","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.cotox.2022.100373_bib22","article-title":"Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components","volume":"9","author":"Turner","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cotox.2022.100373_bib23","first-page":"328","article-title":"HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview","volume":"22","author":"Balasubramanian","year":"2021","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.cotox.2022.100373_bib24","first-page":"11","article-title":"Statin induced rhabdomyolysis","volume":"69","author":"Kumar","year":"2021","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.cotox.2022.100373_bib25","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":", statin safety and associated adverse events: a scientific statement from the American heart association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cotox.2022.100373_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/01926233221100414","article-title":"Kidney effects by alternative classes of medicines in patients and relationship to effects in nonclinical toxicity studies","volume":"50","author":"Frazier","year":"2022","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.cotox.2022.100373_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.cotox.2022.100373_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-4939-8651-4_4","article-title":"Nusinersen in the treatment of spinal muscular atrophy","volume":"1828","author":"Goodkey","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cotox.2022.100373_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.cotox.2022.100373_bib30","series-title":"Nusinersen pharmacology\/toxicology review and evaluation","author":"Brown","year":"2016"},{"key":"10.1016\/j.cotox.2022.100373_bib31","first-page":"4667","article-title":"Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters","volume":"268","author":"Stolte","year":"2021","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cotox.2022.100373_bib32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cotox.2022.100373_bib33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.cotox.2022.100373_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cotox.2022.100373_bib35","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/mus.27217","article-title":"Laboratory monitoring of nusinersen safety","volume":"63","author":"Goedeker","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cotox.2022.100373_bib36","first-page":"923","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2021","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cotox.2022.100373_sref37","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.cotox.2022.100373_bib38","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cotox.2022.100373_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care","volume":"16","author":"Luigetti","year":"2020","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.cotox.2022.100373_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cotox.2022.100373_bib41","first-page":"12","article-title":"Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","author":"Gales","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cotox.2022.100373_bib42","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/DDDT.S162913","article-title":"Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis","volume":"13","author":"Mathew","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.cotox.2022.100373_bib43","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/ene.14285","article-title":"Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial","volume":"27","author":"Brannagan","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cotox.2022.100373_sref44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.cotox.2022.100373_bib45","series-title":"Golodirsen clinical pharmacology review","author":"Bilal AbuAsal","year":"2019"},{"key":"10.1016\/j.cotox.2022.100373_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.cotox.2022.100373_bib47","series-title":"VYONDYS 53 (golodirsen) injection, for intravenous use","author":"Therapeutics","year":"2019"},{"key":"10.1016\/j.cotox.2022.100373_sref48","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.cotox.2022.100373_bib49","first-page":"S343","article-title":"Exon-skipping in Duchenne muscular dystrophy","volume":"8","author":"Takeda","year":"2021","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.cotox.2022.100373_bib50","series-title":"Viltolarsen non-clinical review","author":"Freed","year":"2020"},{"key":"10.1016\/j.cotox.2022.100373_bib51","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cotox.2022.100373_bib52","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.cotox.2022.100373_bib53","first-page":"235","article-title":"Pharmacological profile of viltolarsen for the treatment of Duchenne muscular dystrophy: a Japanese experience","volume":"13","author":"Roshmi","year":"2021","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.cotox.2022.100373_bib54","unstructured":"NS Pharma, VILTEPSO (viltolarsen) injection, for intravenous use: US FDA prescribing information."},{"key":"10.1016\/j.cotox.2022.100373_sref55","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cotox.2022.100373_bib56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1358\/dot.2021.57.12.3352740","article-title":"Casimersen for Duchenne muscular dystrophy","volume":"57","author":"Wilton-Clark","year":"2021","journal-title":"Drugs Today"},{"key":"10.1016\/j.cotox.2022.100373_bib57","series-title":"Casimersen non-clinical review","author":"Freed","year":"2021"},{"key":"10.1016\/j.cotox.2022.100373_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/nat.2015.0598","article-title":"Comparative renal toxicopathology of antisense oligonucleotides","volume":"26","author":"Engelhardt","year":"2016","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.cotox.2022.100373_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cotox.2022.100373_bib60","series-title":"Study of SRP-4045 (casimersen) and SRP-4053 (golodirsen) in participants with Duchenne muscular dystrophy","year":"2022"},{"key":"10.1016\/j.cotox.2022.100373_bib61","series-title":"An extension study to evaluate casimersen or golodirsen in patients with Duchenne muscular dystrophy","year":"2018"},{"key":"10.1016\/j.cotox.2022.100373_bib62","series-title":"AMONDYS 45 (casimersen) injection, for intravenous use","author":"Therapeutics","year":"2021"},{"key":"10.1016\/j.cotox.2022.100373_sref63","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cotox.2022.100373_bib64","first-page":"107","article-title":"First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase","volume":"209","author":"Monia","year":"1997","journal-title":"Ciba Found Symp"},{"key":"10.1016\/j.cotox.2022.100373_bib65","series-title":"Antisense drug technology : principles, strategies, and applications","author":"Scott","year":"2007"},{"key":"10.1016\/j.cotox.2022.100373_bib66","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated safety assessment of 2'-O-methoxyethyl chimeric antisense oligonucleotides in NonHuman primates and healthy human volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.cotox.2022.100373_bib67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cotox.2022.100373_bib68","first-page":"a000687","volume":"2","author":"Fox","year":"2010","journal-title":"Paraspeckles, Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.cotox.2022.100373_bib69","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cotox.2022.100373_bib70","doi-asserted-by":"crossref","first-page":"10865","DOI":"10.1093\/nar\/gkz771","article-title":"Kinetic and subcellular analysis of PS-ASO\/protein interactions with P54nrb and RNase H1","volume":"47","author":"Vickers","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cotox.2022.100373_bib71","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1093\/nar\/gkz247","article-title":"Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins","volume":"47","author":"Migawa","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cotox.2022.100373_bib72","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/gtc.12587","article-title":"Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences","volume":"23","author":"Yoshida","year":"2018","journal-title":"Gene Cell"},{"key":"10.1016\/j.cotox.2022.100373_sref73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/nat.2017.0693","article-title":"The effects of 2'-O-methoxyethyl oligonucleotides on renal function in humans","volume":"28","author":"Crooke","year":"2018","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.cotox.2022.100373_bib74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The effects of 2'-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.cotox.2022.100373_sref75","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2016.11.006","article-title":"Inhibition of EGF uptake by nephrotoxic antisense drugs in\u00a0vitro and implications for preclinical safety profiling","volume":"6","author":"Moisan","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cotox.2022.100373_sref76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtn.2018.11.005","article-title":"GalNAc conjugation attenuates the cytotoxicity of antisense oligonucleotide drugs in renal tubular cells","volume":"14","author":"Sewing","year":"2019","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Current Opinion in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468202022000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468202022000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:17:53Z","timestamp":1762838273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468202022000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":76,"alternative-id":["S2468202022000560"],"URL":"https:\/\/doi.org\/10.1016\/j.cotox.2022.100373","relation":{},"ISSN":["2468-2020"],"issn-type":[{"value":"2468-2020","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nephrotoxicity of marketed antisense oligonucleotide drugs","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cotox.2022.100373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100373"}}